Review on the clinical use of eribulin mesylate for the treatment of breast cancer.
about
Efficacy and safety of doublet versus single agent as salvage treatment for metastatic breast cancer pretreated with anthracyclines and taxanes: a systematic review and meta-analysis.Identification of pyrrolopyrimidine derivative PP-13 as a novel microtubule-destabilizing agent with promising anticancer propertiesEffect of bis(hydroxymethyl) alkanoate curcuminoid derivative MTH-3 on cell cycle arrest, apoptotic and autophagic pathway in triple-negative breast adenocarcinoma MDA-MB-231 cells: An in vitro study.
P2860
Review on the clinical use of eribulin mesylate for the treatment of breast cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Review on the clinical use of eribulin mesylate for the treatment of breast cancer.
@en
type
label
Review on the clinical use of eribulin mesylate for the treatment of breast cancer.
@en
prefLabel
Review on the clinical use of eribulin mesylate for the treatment of breast cancer.
@en
P2860
P1476
Review on the clinical use of eribulin mesylate for the treatment of breast cancer
@en
P2093
Olexiy Aseyev
P2860
P304
P356
10.1517/14656566.2016.1146683
P407
P577
2016-02-17T00:00:00Z